TheraRadar
Clinical-Stage Companies / GB002

GB002

Pre-Approval PRO BETA
3
Total Trials
3
Phase 3
0
Phase 2
1
Recruiting
50
Score

Pipeline by Phase

Phase 3
3
Phase 2
Phase 1

Therapeutic Focus

Pulmonary Arterial Hypertension Pulmonary Hypertension Associated With Interstitial Lung Disease

Clinical Trials (3)

NCT05934526 Phase 3 COMPLETED

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Started: 12/28/2023

NCT06274801 Phase 3 ACTIVE NOT RECRUITING

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Started: 9/3/2024

NCT07181382 Phase 3 SUSPENDED

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Started: 2/1/2026

Drug Candidates

Placebo Seralutinib
Activity Status: Active
Last Trial Started: 2/1/2026
Last Trial Ended: 12/22/2025
Trials (12 months): 1
Completed Trials: 1
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.